Literature DB >> 25601661

Gastrointestinal bleeding. Gastrointestinal bleeding risk is increased by novel anticoagulants.

Don C Rockey1.   

Abstract

A report has demonstrated that in patients with atrial fibrillation the novel oral anticoagulant, dabigatran, increases the risk of gastrointestinal bleeding by nearly twofold compared with warfarin. Here, the risk of gastrointestinal bleeding associated with anticoagulants and antiplatelet agents is placed into clinical context and key management principles are emphasized.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25601661     DOI： 10.1038/nrgastro.2015.7

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  10 in total

1.  Risk of bleeding with dabigatran in atrial fibrillation.

Authors:  Inmaculada Hernandez; Seo Hyon Baik; Antonio Piñera; Yuting Zhang
Journal:  JAMA Intern Med       Date:  2015-01       Impact factor: 21.873

2.  Bleeding risk with dabigatran in the frail elderly.

Authors:  Paul Harper; Laura Young; Eileen Merriman
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

3.  Risk of lower and upper gastrointestinal bleeding, transfusions, and hospitalizations with complex antithrombotic therapy in elderly patients.

Authors:  Neena S Abraham; Christine Hartman; Peter Richardson; Diana Castillo; Richard L Street; Aanand D Naik
Journal:  Circulation       Date:  2013-09-11       Impact factor: 29.690

4.  A comparison of results of the US food and drug administration's mini-sentinel program with randomized clinical trials: the case of gastrointestinal tract bleeding with dabigatran.

Authors:  Ilke Sipahi; Seden Celik; Nurdan Tozun
Journal:  JAMA Intern Med       Date:  2014-01       Impact factor: 21.873

5.  Dabigatran and postmarketing reports of bleeding.

Authors:  Mary Ross Southworth; Marsha E Reichman; Ellis F Unger
Journal:  N Engl J Med       Date:  2013-03-13       Impact factor: 91.245

6.  Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study.

Authors:  Morten Lamberts; Gregory Y H Lip; Morten Lock Hansen; Jesper Lindhardsen; Jonas Bjerring Olesen; Jakob Raunsø; Anne-Marie Schjerning Olsen; Per Kragh Andersen; Thomas Alexander Gerds; Emil L Fosbøl; Christian Torp-Pedersen; Gunnar H Gislason
Journal:  Ann Intern Med       Date:  2014-11-18       Impact factor: 25.391

7.  Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease.

Authors:  P D Greenberg; J P Cello; D C Rockey
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

8.  New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis.

Authors:  I Lisanne Holster; Vera E Valkhoff; Ernst J Kuipers; Eric T T L Tjwa
Journal:  Gastroenterology       Date:  2013-03-05       Impact factor: 22.682

Review 9.  Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials.

Authors:  András Komócsi; András Vorobcsuk; Dániel Kehl; Dániel Aradi
Journal:  Arch Intern Med       Date:  2012-11-12

10.  Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.

Authors:  Torben Bjerregaard Larsen; Lars Hvilsted Rasmussen; Flemming Skjøth; Karen Margrete Due; Torbjörn Callréus; Mary Rosenzweig; Gregory Y H Lip
Journal:  J Am Coll Cardiol       Date:  2013-04-03       Impact factor: 24.094
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.